Biocytogen

Animal Models and Cell Lines

>Double Humanized Immune-Checkpoint Mice

B-hPD-1/h4-1BB mice


Basic characteristics

1.png 


Targeting strategy


image.png


Protein expression analysis 

1.png

Fig 1.  Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/h4-1BB mice were analyzed by flow cytometry. Mouse 4-1BB+ T cells were detectable in the WT C57BL/6 mice, while human 4-1BB+ T cells were detectable in the homozygous B-hPD-1/h4-1BB mice.

 

2.png

Fig 2. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/h4-1BB mice were analyzed by flow cytometry. Mouse PD-1+ T cells were detectable in the WT C57BL/6 mice, while human PD-1+ T cells were detectable in the homozygous B-hPD-1/h4-1BB mice.

 

Combination therapy of PD-1 (Keytruda) mAb and 4-1BB antibody (Urelumab Analog) (MC38 cell line)

image.png

Fig 3. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/h4-1BB mice.

Mice were grouped (n=5) when the tumor size was approximately 150 ± 50mm3 (n=6). Anti-hPD-1 antibody and anti-h4-1BB antibody significantly inhibited tumor growth in the homozygous B-hPD-1/h4-1BB mice, suggesting that B-hPD-1/h4-1BB mouse model is an effective tool for in vivo efficacy evaluation of hPD-1 and h4-1BB antibody combination therapy. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.



 

【Return list】
* Contact Name
* Quantity
Telephone No.
Email
* Shipping address
Verification code captcha
© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud